Human endometrial stem cells confer enhanced myocardial salvage and regeneration by paracrine mechanisms

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 10, 2013, Pages 1247-1260

  Jiang, Zhi ^a   Hu, Xinyang ^a   Yu, Hong ^a   Xu, Yinchuan ^a   Wang, Lihan ^a   Chen, Han ^a   Chen, Huiqiang ^a   Wu, Rongrong ^a   Zhang, Zhaocai ^a   Xiang, Chunsheng ^b   Webster, Keith A ^c   Wang, Jian an ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Endometrial stem cells; Myocardial infarction; Paracrine; Regeneration

Indexed keywords

RATTUS;

ANGIOGENESIS; ANIMAL; APOPTOSIS; ARTICLE; CYTOLOGY; ENDOMETRIAL STEM CELLS; ENDOMETRIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HEART MUSCLE; HUMAN; PARACRINE; POSITRON EMISSION TOMOGRAPHY; RAT; REGENERATION; STEM CELL;

ANGIOGENESIS; APOPTOSIS; ENDOMETRIAL STEM CELLS; MYOCARDIAL INFARCTION; PARACRINE; REGENERATION;

ANIMALS; ENDOMETRIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RATS; REGENERATION; STEM CELLS;

EID: 84888364958     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12100     Document Type: Article

References (46)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update. Circulation. 2012; 125: e2-220.
2. Beitnes JO, Lunde K, Brinchmann JE, et al. Stem cells for cardiac repair in acute myocardial infarction. Expert Rev Cardiovasc Ther. 2011; 9: 1015-25.
3. Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther. 2011; 22: 3-17.
4. Malliaras K, Li T-S, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells/clinical perspective. Circulation. 2012; 125: 100-12.
5. Cui C-H, Uyama T, Miyado K, et al. Menstrual blood-derived cells confer human dystrophin expression in the murine model of duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell. 2007; 18: 1586-94.
6. Meng X, Ichim T, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007; 5: 57.
7. Patel AN, Silva F. Menstrual blood stromal cells: the potential for regenerative medicine. Regen Med. 2008; 3: 443-4.
8. Dimitrov R, Timeva T, Kyurkchiev D, et al. Characterization of clonogenic stromal cells isolated from human endometrium. Reproduction. 2008; 135: 551-8.
9. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105: 93-8.
10. Pearl Jeremy I, Lee Andrew S, Leveson-Gower Dennis B, et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell. 2011; 8: 309-17.
11. Ranganath Sudhir H, Levy O, Inamdar Maneesha S, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10: 244-58.
12. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006; 98: 1076-84.
13. Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 1982; 50: 101-16.
14. Hu X, Yu SP, Fraser JL, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008; 135: 799-808.
15. Morooka M, Kubota K, Kadowaki H, et al. 11C-methionine PET of acute myocardial infarction. J Nucl Med. 2009; 50: 1283-7.
16. Timmers L, Lim SK, Arslan F, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2008; 1: 129-37.
17. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20: 661-9.
18. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation/novelty and significance. Circ Res. 2010; 107: 913-22.
19. Xaymardan M, Sun Z, Hatta K, et al. Uterine cells are recruited to the infarcted heart and improve cardiac outcomes in female rats. J Mol Cell Cardiol. 2012; 52: 1265-73.
20. Loffredo Francesco S, Steinhauser Matthew L, Gannon J, et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011; 8: 389-98.
21. Dai B, Huang W, Xu M, et al. Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function. J Am Coll Cardiol. 2011; 58: 2118-27.
22. Engel FB, Hsieh PCH, Lee RT, et al. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA. 2006; 103: 15546-51.
23. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol. 2008; 295: H2308-14.
24. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59: S21-6.
25. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004; 15: 205-13.
26. Cai W, Guzzo RM, Wei K, et al. A nodal-to-TGFβ cascade exerts biphasic control over cardiopoiesis. Circ Res. 2012; 111: 876-81.
27. Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J. 2012; 164: 715-27. e1.
28. Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2012; 14: 91-105.
29. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012; 2: CD006536.
30. Mirotsou M, Jayawardena TM, Schmeckpeper J, et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011; 50: 280-9.
31. Hida N, Nishiyama N, Miyoshi S, et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells. 2008; 26: 1695-704.
32. Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology. 2009; 113: 155-60.
33. Skalnikova H, Motlik J, Gadher SJ, et al. Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics. 2011; 11: 691-708.
34. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004; 95: 187-95.
35. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997; 88: 435-7.
36. Matsuura K, Honda A, Nagai T, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J Clin Invest. 2009; 119: 2204-17.
37. Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 2012; 13: 1153-75.
38. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 1847-57.
39. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355: 1210-21.
40. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004; 109: 1615-22.
41. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010; 56: 721-34.
42. Murphy M, Wang H, Patel A, et al. Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med. 2008; 6: 45.
43. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 2277-86.
44. Penn MS, Ellis S, Gandhi S, et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012; 110: 304-11.
45. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308: 2369-79.
46. Zhong Z, Patel A, Ichim T, et al. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med. 2009; 7: 15.